Unadjusted effects on mortality and interaction for myelodysplastic malignancies versus solid tumours
| Variables | IQR | Myelodysplastic malignancies (n=68) | Solid tumours (n=388) | p Value Interaction | ||
|---|---|---|---|---|---|---|
| Crude HR (95% CI) | p Value | Crude HR (95% CI) | p Value | |||
| hsTnT, ng/mL | 0.007 | 1.24 (1.08 to 1.42) | 0.001 | 1.35 (1.25 to 1.44) | <0.001 | 0.238 |
| ln(NT-proBNP), pg/mL | 1.465 | 1.58 (0.93 to 2.69) | 0.093 | 1.66 (1.39 to 1.98) | <0.001 | 0.140 |
| ln(MR-proANP), pmol/L | 0.821 | 1.27 (0.64 to 2.49) | 0.495 | 1.59 (1.33 to 1.91) | <0.001 | 0.242 |
| MR-proADM, nmol/L | 0.280 | 2.10 (1.42 to 3.10) | <0.001 | 1.24 (1.16 to 1.32) | <0.001 | 0.001 |
| CT-proET-1, pmol/L | 27.858 | 1.74 (1.09 to 2.76) | 0.020 | 1.25 (1.18 to 1.33) | <0.001 | 0.025 |
| ln(copeptin), pmol/L | 1.049 | 1.55 (0.73 to 3.29) | 0.251 | 1.57 (1.36 to 1.83) | <0.001 | 0.177 |
Cox proportional hazard model of cardiovascular hormones and hsTnT for haematological myelodysplastic and solid tumours and the p value for interaction between the groups are shown. HRs refer to a 1-IQR increase in continuous variables.
Fonts in bold indicate statistical significance (p<0.05).
CT-proET-1, C-terminal pro endothelin-1; hsTnT, high-sensitive troponin T; MR-proADM, mid-regional pro-adrenomedullin; MR-proANP, mid-regional pro-atrial natriuretic peptide; NT-proBNP, N-terminal pro B-type natriuretic peptide.